reported that human BRAF‐mutant melanoma cells display single‐cell transcriptional heterogeneity, which results in transient upregulation of several resistance genes in a small portion of cells, such as AXL, WNT5, EGFR, JUN, and PDGFRB, leading to development of drug resistance and survival of cancer cells from vemurafenib therapy. The gene discussed is BRAF; the disease is melanoma.